immunosuppressive therapies (TNF-α inhibitors) [13 -20]. Studies to identify clinical risk factors for IA are often diffi cult for several reasons: First, studies may be limited by small numbers of patients because of the low incidence of IA in some patient groups. Second, there are important methodologic issues, specifi cally regarding the impact of risk factors over time, and defi ning the period at risk. Finally, because of diagnostic limitations in non-traditional hosts, it is diffi cult to understand the true impact of IA in some groups. Herein, clinical risk factors for IA are reviewed, with a focus on emerging patient populations at risk for IA.
Hematopoietic stem cell transplant (HSCT) recipients
Because of the poor outcomes associated with invasive fungal infections in HSCT patients there has been much interest in prevention and treatment measures in hopes of improving survival. Identifi cation of clinical risk factors for IA has been well studied in HSCT recipients, and important risk factors include prolonged neutropenia, corticosteroid use (dose and duration), underlying diseases and transplant-related variables (Table 1) [6,11,12,21 -23] . In addition, the environment as a risk factor, including concentration of Aspergillus spore counts in air samples, and impact of hospital construction on nosocomial IA, has become important [9] . Recently, clinical risk factors for IA and other invasive fungal infections have been associated with timing of IA in relation to transplant (early, Ͻ 40 days; or late, 40 -80 or 100 days) [21,23 -25] . For example, risk
Introduction
Invasive aspergillosis (IA) is an important cause of morbidity and mortality in immunocompromised patients. Despite improvements in the antifungal armamentarium and in diagnostic modalities, mortality remains unacceptably high [1, 2] . There is much interest in development of prevention measures, and identifi cation of clinical risk factors will play a key role in focusing prevention efforts.
There are many risk factors for IA, which can be related to underlying disease of the host (malignancy, transplant type, age); co-morbidities (graft-versus-host disease, diabetes, cytomegalovirus infection, renal or liver dysfunction, COPD, post-surgery); medications (steroids, TNF-α inhibitors, chemotherapy); environment or nosocomial risk factors (air fi ltration, water, hospital construction), and those that deal with the host/pathogen interactions [3 -12] . Risk factors for IA have been studied extensively in patients with hematologic malignancy and transplants; however, clinical risk factors are less well defi ned for nontraditional patient groups. Several emerging groups at risk for IA include intensive care unit (ICU) patients; patients with chronic obstructive pulmonary disease (COPD); post-operative patients; HIV patients and patients on newer factors for late IA include GVHD and its treatment (corticosteroid therapy), lymphopenia and viral infection [21] . In contrast, early-onset IA is associated with neutropenia, host (underlying malignancy) or transplant (stem cell source) variables. This aspect of risk period post-transplant has important implications for prevention efforts.
Viral lower respiratory tract infections have been an important problem in HSCT patients and increase the risk of IA [25 -27] . This was confi rmed recently by Martino and colleagues, who evaluated risk factors for IA among reducedintensity allogeneic HSCT patients [27] . Among 219 patients, 27 (12.3%) developed proven or probable IA, as defi ned by standard criteria [28] . Independent risk factors for IA were steroid therapy for moderate-to-severe GVHD, CMV disease and lower respiratory tract infection caused by respiratory viruses. The most common viruses causing lower respiratory tract infection in patients with subsequent IA were infl uenza A or B, parainfl uenza, adenovirus, and metapneumovirus. It is important to reinforce the role that respiratory viruses may play in development of IA, especially with the emergence of novel H1N1 infection and other viruses.
Solid organ transplant recipients
Invasive aspergillosis in solid organ transplant patients continues to be a major cause of morbidity and mortality. Incidence of IA ranges from 2 -40% and is dependent on the organ transplanted [29 -32] . The most important risk factors for IA, common to all SOT patients, are the net state of immunosuppression and intensity of the immunosuppressive regimen, which may be affected by corticosteroid dose, treatment for rejection and immunomodulatory viruses such as CMV [31 -33] . There are many other organspecifi c clinical risk factors for IA, as described in Table 2 ; however, because of the rarity of IA in some transplant populations, studies evaluating clinical risk factors are uncommon [30 -36] .
A recent case-control study by Gavalda and colleagues, as part of the Spanish Network for Research on Infection in Transplantation, highlighted some important clinical risk factors for IA and the relationship of period of IA risk post-transplantation [37] . Controls included the two patients who underwent the same type of transplant before and after the enrolled IA case, provided a minimum of 18-month follow-up was documented. Overall, 156 cases of proven or probable IA were diagnosed; 80 (51.3%) in liver recipients, 47(30.1%) in heart recipients, 17(10.9%) in lung recipients, 10(6.4%) in kidney recipients, and 2(1.3%) in pancreas-kidney recipients. Independent risk factors for early IA ( Ͻ 3 months after transplantation) included use of vascular amines, additional ICU stay, posttransplantation renal failure or hemodialysis, CMV disease or Ͼ 1 episode of bacterial infection. In contrast, older age, renal failure, immunosuppressive agents, CMV disease, Ͼ 1 bacterial infection, chronic graft rejection and immunosuppressive-related neoplasm were independent risk factors for late IA ( Ͼ 3 months after transplantation) [37] Additional data on clinical risk factors for IA in solid organ transplant recipients, especially renal or heart transplant patients, is needed.
Intensive care unit patients
There has been increasing interest in the emergence of IA among critically ill patients, especially those admitted to the ICU [4, 13, 38, 39] . Although IA incidence in the ICU Rello and colleagues reported a summary of eight cases and a review of the literature and noted that corticosteroid treatment, usually at daily oral doses of Ͼ 20 mg of prednisone, and previous antibiotic use were common among IA patients [3] . In several other review articles, late-stage COPD, prolonged steroids, viral infection, and inhaled steroids are suggested as possible risk factors; however, these fi ndings were derived from anecdotal case reports and not controlled studies [45, 47, 48] . Guinea and colleagues, describing a large retrospective cohort of patients from a single institution, determined four independent risk factors for probable IA among patients with COPD: admission to the ICU (OR 2.4, 95% CI 1.19 -5.29); previous antibiotic treatment (OR 2.57, 95% CI 1.2 -5.49); and cumulative steroid dose in past 3 months prior to admission (OR 2.98, 95% CI 1.26 -7.06) or from admission to diagnosis (OR 2.02, 95% CI 1.2 -5.49) [15] . Clearly, there is a great need to identify risk factors for IA among patients with underlying COPD, and larger, adequately powered multi-center studies will be necessary.
HIV-infected patients
Invasive aspergillosis is a relatively uncommon infection in patients with acquired immune defi ciency syndrome (AIDS), with an incidence rate of 3.5 cases per 1000 person-years [19] . A recent study using 2003 National Inpatient Sample (NIS) administrative data reported that HIV infection was an underlying condition in 3.7% of total aspergillosis cases, with an incidence of 0.43% [49] . Fortunately, it does not appear that the incidence if IA in HIV-infected patients is increasing. In fact, as the population of AIDS patients with has been reported to be as high as 7%, the true incidence is diffi cult to determine because of several important limitations of IA diagnosis in ICU patients [13] . For example, classic radiographic signs of IA ( ' halo ' or ' air crescent ' ) seen in neutropenic patients are not routinely present in ICU patients, determination of colonization vs. infection is problematic and diagnostic studies are less sensitive and have not been validated adequately in non-neutropenic patient populations [13] . Recently, Meersseman and colleagues, in a single-center study, investigated the use of bronchoalveolar lavage fl uid (BAL) galactomannan testing as a diagnostic modality for ICU patients [40] . Among 110 patients eligible, 29 had proven IA [28] . BAL testing proved to be useful in this population, with sensitivity of 88% and 87%, respectively. Moreover, the sensitivity of serum galactomannan was only 42%. As diagnostic methods for IA improve and additional immunosuppressive agents are developed, an increased incidence of IA in ICU patients should be expected. Important non-traditional ICU patients at risk for IA include those with cirrhosis, COPD, solidorgan malignancy, HIV infection, malnutrition, and postsurgical patients and those on immunosuppressive therapies. Several of these groups will be discussed below.
Post-operative invasive aspergillosis
Post-operative IA is an uncommon and underestimated complication of surgery [17, 18] . This entity is rare, but approximately 500 cases have been reported to date [17] . Jensen and colleagues estimated an incidence of 2 cases/10,000 surgical procedures [18] . Infection may arise after colonization of surgical sites from airborne Aspergillus spores, and the onset of disease is variable, ranging from days to months after the surgical procedure [17, 18] . Because of the rarity of post-operative IA, it has been diffi cult to determine clinical risk factors. As noted in recent studies, post-operative IA usually occurs among patients without classic predisposing conditions for aspergillosis; however, in some cases, the disease has affected SOT patients and others receiving corticosteroids [17, 18] . Highrisk procedures appear to be cardiothoracic surgery, vascular surgery, and ophthamologic or dental surgery. Although the presumed primary source of infection is colonization of surgical sites from airborne Aspergillus spores, it is unclear if elevated Aspergillus spore levels in operating rooms is a risk factor [18, 41] .
Patients with COPD
Among immunocompetent patients there have been increasing descriptions of the importance of COPD as a risk factor or an underlying co-morbidity in patients with IA [4, 14, 15, [42] [43] [44] . From these studies, mostly case reports, single-center severe immunodefi ciency decreases because of highly active antiretroviral therapy (HAART), the incidence of aspergillosis will probably decrease, as well.
Aspergillus infections most often occur in HIV patients with advanced AIDS and immunosuppression, or in those patients with identifi ed risk factors for the development of invasive disease. The most important of these clinical risk factors are neutropenia, frequently secondary to medications such as zidovudine, trimethoprim-sulfamethoxazole, and antineoplastic agents; and corticosteroids. Neutropenia or corticosteroid use has been identifi ed in almost half of cases of IA HIV-infected patients [50] . Other possible clinical risk factors include broad-spectrum antibiotic administration, alcohol or marijuana use, underlying lung disease, a prior episode of P. jiroveci pneumonia, CD4 cell counts Ͻ 100 cells/ μ l, and leukocytopenia [19,51 -53] .
Patients receiving newer immunosuppressive agents
The number of patients receiving immunosuppressive agents has increased over the past decade and is expected to increase substantially in the near future. Newer biologic medicines, including the tumor necrosis factor (TNF)-α inhibitors infl iximab, adalimumab, etanercept, certolizumab and golimumab, have been approved for the treatment of one or more of a number of diseases including rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn ' s disease, juvenile idiopathic arthritis and ankylosing spondylitis. Moreover, immunosuppressive agents such as abatacept, anakinra and rituximab are used increasingly. TNF-α plays an important role in regulation of the immune response, and use of TNF-α inhibitors is associated with an increased incidence of serious infections caused by a broad spectrum of pathogens, including viral, bacterial, mycobacterial, fungal, and protozoal organisms [20,54,55] . There have been numerous case reports describing IA among patients receiving TNF-α inhibitors, recently summarized by Tsiodras and colleagues [20, 56, 57] . The authors reviewed published reports from January 1966 through 1 June 2007 to determine the association of fungal infections with TNF-α blockade. The authors identifi ed 64 cases of proven or probable aspergillosis, mostly pulmonary disease in HSCT patients. The most common TNF-α inhibitor was infl iximab, used in 75% of cases. Among cases with data available, overall mortality was 82%. Currently, data regarding impact of these agents on risk of IA are limited; however, vigilance in the care of these patients is warranted while studies are ongoing.
Conclusions and future perspectives
There has been much improvement in the care of patients with IA in the past decade. In concert with improved antifungal therapy, newer diagnostic modalities are decreasing the time to diagnosis, and improving the sensitivity of diagnosis of IA. We have benefi tted from recent research into clinical risk factors for IA, especially the importance of a well-defi ned risk period among transplant patients. An enormous future challenge will be identifi cation of precise clinical risk factors in non-traditional patient populations, including patients in the ICU setting, those with COPD or HIV-infection and those receiving newer immunosuppressive therapies. Because of the rarity of IA in some of these non-traditional host groups, large, observational studies or case-control studies may be required to elucidate clinical risk factors and will help to focus prevention efforts.
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